Lexaria Bioscience Corp.

Lexaria Bioscience Corp. reported a net loss attributable to shareholders of $1.99 million for the three months ended May 31, 2026, with no revenue generated during the quarter. For the nine months ended May 31, 2026, the net loss was $5.04 million on $20,000 in revenue. The company raised $6.5 million from share sales but noted substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.

Lexaria Bioscience Corp. reported its financial results for the quarter ended February 28, 2026. The company significantly increased its cash position to $5.13 million, up from $1.80 million at August 31, 2025. This substantial growth in cash, alongside a rise in total current assets to $5.77 million, indicates improved liquidity and a stronger financial position for the company.

Lexaria Bioscience Corp. reported a substantial increase in its cash position, reaching $5.13 million for the quarter ended February 28, 2026, up from $1.80 million as of August 31, 2025. This growth contributed to a rise in total current assets to $5.77 million and total assets to $6.49 million, indicating improved liquidity.